Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.36 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19861173 | 0.94 | PAOX (0.53) | PAOXMEN1KMT2AHPGDSLC6A5 | |
| SCHEMBL19861312 | 0.92 | PAOX (0.57) | PAOXMEN1KMT2ASLC6A5ALDH1A1 | |
| SCHEMBL19861244 | 0.92 | PAOX (0.57) | PAOXMEN1KMT2ASLC6A5ALDH1A1 | |
| SCHEMBL1963990 | 0.87 | HPGD (0.42) | PAOXMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL23518488 | 0.85 | MEN1 (0.52) | PAOXMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL12335215 | 0.82 | MEN1 (0.42) | PAOXMEN1KMT2ASLC6A5ALDH1A1 | |
| SCHEMBL24977935 | 0.82 | PAOX (0.41) | PAOXMEN1KMT2ASLC6A5ALDH1A1 | |
| SCHEMBL4782817 | 0.82 | HPGD (0.47) | MEN1KMT2AHPGDALDH1A1KDM4E | |
| SCHEMBL854283 | 0.81 | PTGS1 (0.47) | MEN1KMT2AHPGDALDH1A1KDM4E | |
| SCHEMBL4308618 | 0.81 | CASP2 (0.50) | MEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844379-B2 | Conjugated antisense compounds and their use | IONIS PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2018-04-19 | — | — | US | disclosed |
| US-9890198-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2018-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | FKBP5, FKBP1B, MALT1 | PAOX 3995/4885MEN1 523/4885KMT2A 4492/4885 |
| US-10844379-B2 | Conjugated antisense compounds and their use | CSGALNACT1, GALNT1, GALNT6 | PAOX 2450/4885MEN1 2908/4885KMT2A 1580/4885 |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | PAOX 4000/4885MEN1 786/4885KMT2A 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.